Response to antiretroviral therapy undergone by HIV/AIDS patients

HIV/AIDS, with new cases thereof coming up year after year, is a fastgrowing disease. In order to inhibit HIV replication, ARV is administered to HIV/AIDS patients throughout his life-time. Continuous monitoring for the detection of its desired result ought to be condu...

Full description

Bibliographic Details
Main Authors: Nanang Munif Yasin, Hesaji Maranty, Wahyu Roossi Ningsih
Format: Article
Language:English
Published: Universitas Gadjah Mada 2011-07-01
Series:Indonesian Journal of Pharmacy
Subjects:
Online Access:http://indonesianjpharm.farmasi.ugm.ac.id/index.php/3/article/view/632/506
_version_ 1818936616004091904
author Nanang Munif Yasin
Hesaji Maranty
Wahyu Roossi Ningsih
author_facet Nanang Munif Yasin
Hesaji Maranty
Wahyu Roossi Ningsih
author_sort Nanang Munif Yasin
collection DOAJ
description HIV/AIDS, with new cases thereof coming up year after year, is a fastgrowing disease. In order to inhibit HIV replication, ARV is administered to HIV/AIDS patients throughout his life-time. Continuous monitoring for the detection of its desired result ought to be conducted. This study is aimed to find out the response of the ARV therapy undergone by the HIV/AIDS patients hospitalized in a teaching hospital in Yogyakarta. Descriptive non-experimental design was used for the study. The data were obtained retrospectively from medical records of 71 patients who met the inclusion and exclusion criteria. The data were analyzed descriptively.The research findings indicated that of the first-line ARV therapy, zidovudine+lamivudine+nevirapine (AZT+3TC+NVP) was mostly used (61.97%). It was found that all of the ARV types used were in accordance with the National Therapy Antiretroviral Guidelines (2007) from Health Ministry Department, Indonesia. As observed further, 61 (92.80%), 40 (85.00%), and 20 (85.00%) patients had their CD4 increased; 66 (72.72%), 44 (75.00%), 24 (79.17%) had gained weight; and 71 (100%), 55 (100%), and 31 (96.77%) had survived the disease after 6, 12, and 24 months undergoing ARV therapy. However, the increase in CD4 after six-month therapy was not always attended by the increase in weight. To conclude, this phenomenon indicated good immune and clinical responses.
first_indexed 2024-12-20T05:38:53Z
format Article
id doaj.art-d93a8f5cdec84fa195ab41ac449e498a
institution Directory Open Access Journal
issn 2338-9427
2338-9486
language English
last_indexed 2024-12-20T05:38:53Z
publishDate 2011-07-01
publisher Universitas Gadjah Mada
record_format Article
series Indonesian Journal of Pharmacy
spelling doaj.art-d93a8f5cdec84fa195ab41ac449e498a2022-12-21T19:51:32ZengUniversitas Gadjah MadaIndonesian Journal of Pharmacy2338-94272338-94862011-07-01223212222http://dx.doi.org/10.14499/indonesianjpharm0iss0pp212-222Response to antiretroviral therapy undergone by HIV/AIDS patientsNanang Munif Yasin0Hesaji Maranty1Wahyu Roossi Ningsih2Fakultas Farmasi, Universitas Gadjah Mada Sekip Utara, Yogyakarta, 55281, Indonesia Fakultas Farmasi, Universitas Gadjah Mada Sekip Utara, Yogyakarta, 55281, Indonesia Fakultas Farmasi, Universitas Gadjah Mada Sekip Utara, Yogyakarta, 55281, Indonesia HIV/AIDS, with new cases thereof coming up year after year, is a fastgrowing disease. In order to inhibit HIV replication, ARV is administered to HIV/AIDS patients throughout his life-time. Continuous monitoring for the detection of its desired result ought to be conducted. This study is aimed to find out the response of the ARV therapy undergone by the HIV/AIDS patients hospitalized in a teaching hospital in Yogyakarta. Descriptive non-experimental design was used for the study. The data were obtained retrospectively from medical records of 71 patients who met the inclusion and exclusion criteria. The data were analyzed descriptively.The research findings indicated that of the first-line ARV therapy, zidovudine+lamivudine+nevirapine (AZT+3TC+NVP) was mostly used (61.97%). It was found that all of the ARV types used were in accordance with the National Therapy Antiretroviral Guidelines (2007) from Health Ministry Department, Indonesia. As observed further, 61 (92.80%), 40 (85.00%), and 20 (85.00%) patients had their CD4 increased; 66 (72.72%), 44 (75.00%), 24 (79.17%) had gained weight; and 71 (100%), 55 (100%), and 31 (96.77%) had survived the disease after 6, 12, and 24 months undergoing ARV therapy. However, the increase in CD4 after six-month therapy was not always attended by the increase in weight. To conclude, this phenomenon indicated good immune and clinical responses.http://indonesianjpharm.farmasi.ugm.ac.id/index.php/3/article/view/632/506HIV/AIDSantiretroviraltherapy responseCD4counthospital
spellingShingle Nanang Munif Yasin
Hesaji Maranty
Wahyu Roossi Ningsih
Response to antiretroviral therapy undergone by HIV/AIDS patients
Indonesian Journal of Pharmacy
HIV/AIDS
antiretroviral
therapy response
CD4count
hospital
title Response to antiretroviral therapy undergone by HIV/AIDS patients
title_full Response to antiretroviral therapy undergone by HIV/AIDS patients
title_fullStr Response to antiretroviral therapy undergone by HIV/AIDS patients
title_full_unstemmed Response to antiretroviral therapy undergone by HIV/AIDS patients
title_short Response to antiretroviral therapy undergone by HIV/AIDS patients
title_sort response to antiretroviral therapy undergone by hiv aids patients
topic HIV/AIDS
antiretroviral
therapy response
CD4count
hospital
url http://indonesianjpharm.farmasi.ugm.ac.id/index.php/3/article/view/632/506
work_keys_str_mv AT nanangmunifyasin responsetoantiretroviraltherapyundergonebyhivaidspatients
AT hesajimaranty responsetoantiretroviraltherapyundergonebyhivaidspatients
AT wahyuroossiningsih responsetoantiretroviraltherapyundergonebyhivaidspatients